Dysbindin (DTNBP1) - A role in psychotic depression?

Journal of Psychiatric Research

Volumn 45, Issue 5, 2011, Pages 588-595

  Domschke, Katharina ^a   Lawford, Bruce ^b,c   Young, Ross ^c   Voisey, Joanne ^c   Morris, C Phillip ^c   Roehrs, Tilmann ^a   Hohoff, Christa ^a   Birosova, Eva ^d   Arolt, Volker ^a   Baune, Bernhard T ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

DTNBP1; Dysbindin; Genetic; Glutamate; Major depression; Psychotic depression

Indexed keywords

DYSBINDIN;

ADULT; AFFECTIVE PSYCHOSIS; ALLELE; ARTICLE; BECK DEPRESSION INVENTORY; CHI SQUARE TEST; CONTROLLED STUDY; DEPRESSIVE PSYCHOSIS; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CARRIER PROTEINS; CHI-SQUARE DISTRIBUTION; CHROMOSOMES, HUMAN, PAIR 6; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS;

EID: 79955030482     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.09.014     Document Type: Article

References (64)

1. Abou Jamra R., Schmael C., Cichon S., Rietschel M., Schumacher J., Nöthen M.M. The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic boundaries?. Schizophrenia Bulletin 2006, 32:599-608.
2. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974, 19:716-723.
3. APA Diagnostic and statistical manual of mental disorder 2004, Text Revision, American Psychiatric Association, Washington, D.C. 4th ed.
4. Arias B., Serretti A., Mandelli L., Gastó C., Catalán R., Ronchi D.D., et al. Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenetics and Genomics 2009, 19:121-128.
5. Barrantes-Vidal N., Ros-Morente A., Kwapil T.R. An examination of neuroticism as a moderating factor in the association of positive and negative schizotypy with psychopathology in a nonclinical sample. Schizophrenia Research 2009, 115:303-309.
6. Baune B.T., Hohoff C., Mortensen L.S., Deckert J., Arolt V., Domschke K. Serotonin transporter polymorphism (5-HTTLPR) association with melancholic depression: a female specific effect?. Depression and Anxiety 2008, 25:920-925.
7. Benson M.A., Newey S.E., Martin-Rendon E., Hawkes R., Blake D.J. Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. The Journal of Biological Chemistry 2001, 276:24232-24241.
8. Bray N.J., Preece A., Williams N.M., Moskvina V., Buckland P.R., Owen M.J., et al. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Human Molecular Genetics 2005, 14:1947-1954.
9. Carter K.W., McCaskie P.A., Palmer L.J. SimHap GUI: an intuitive graphical user interface for genetic association analysis. BMC Bioinformatics 2008, 25:557.
10. Coryell W., Pfohl B., Zimmerman M. The clinical and neuroendocrine features of psychotic depression. The Journal of Nervous and Mental Disease 1984, 172:521-528.
11. Davidovich O., Kimmel G., Shamir R. GEVALT: an integrated software tool for genotype analysis. BMC Bioinformatics 2007, 8:36.
12. Fallgatter A.J., Ehlis A.C., Herrmann M.J., Hohoff C., Reif A., Freitag C.M., Deckert J. DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patients - support for the glutamate hypothesis of schizophrenias. Genes, Brain and Behavior 2010, 9:489-497.
13. Fallgatter A.J., Herrmann M.J., Hohoff C., Ehlis A.C., Jarczok T.A., Freitag C.M., et al. DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals. Neuropsychopharmacology 2006, 31:2002-2010.
14. Funke B., Finn C.T., Plocik A.M., Lake S., DeRosse P., Kane J.M., et al. Association of the DTNBP1 locus with schizophrenia in a U.S. population. American Journal of Human Genetics 2004, 2004(75):891-898.
15. Gaudiano B.A., Young D., Chelminski I., Zimmerman M. Depressive symptom profiles and severity patterns in outpatients with psychotic vs nonpsychotic major depression. Comprehensive Psychiatry 2008, 49:421-429.
16. Glassman A.H., Roose S.P. Delusional depression. A distinct clinical entity?. Archives of General Psychiatry 1981, 38:424-427.
17. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry 2001, 158:1367-1377.
18. Gomez R.G., Fleming S.H., Keller J., Flores B., Kenna H., DeBattista C., et al. The neuropsychological profile of psychotic major depression and its relation to cortisol. Biological Psychiatry 2006, 60:472-478.
19. Halperin E., Kimmel G., Shamir R. Tag SNP selection in genotype data for maximizing SNP prediction accuracy. Bioinformatics 2005, 21:i195-i203.
20. Hapmap The International Hapmap Consortium. The International HapMap Project. Nature 2003, 789-796.
21. Heresco-Levy U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opinion on Emerging Drugs 2005, 10:827-844.
22. Keller J., Shen L., Gomez R.G., Garrett A., Solvason H.B., Reiss A., et al. Hippocampal and amygdalar volumes in psychotic and nonpsychotic unipolar depression. American Journal of Psychiatry 2008, 165:872-880.
23. Kempf L., Nicodemus K.K., Kolachana B., Vakkalanka R., Verchinski B.A., Egan M.F., et al. Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genet 2008, 4(11):e1000252.
24. Kim J.J., Mandelli L., Pae C.U., De Ronchi D., Jun T.Y., Lee C., et al. Is there protective haplotype of dysbindin gene (DTNBP1) 3 polymorphisms for major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32:375-379.
25. Kirov G., Ivanov D., Williams N.M., Preece A., Nikolov I., Milev R., et al. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biologial Psychiatry 2004, 55:971-975.
26. Lattuada E., Serretti A., Cusin C., Gasperini M., Smeraldi E. Symptomatologic analysis of psychotic and non-psychotic depression. Journal of Affective Disorders 1999, 54:183-187.
27. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. American Journal of Human Genetics 2003, 73:34-48.
28. Luciano M., Miyajima F., Lind P.A., Bates T.C., Horan M., Harris S.E., et al. Variation in the dysbindin gene and normal cognitive function in three independent population samples. Genes, Brain and Behavior 2009, 8:218-227.
29. Lykouras E., Malliaras D., Christodoulou G.N., Papakostas Y., Voulgari A., Tzonou A., et al. Delusional depression: phenomenology and response to treatment. A prospective study. Acta Psychiatrica Scandinavica 1986, 73:324-329.
30. Maier W. Common risk genes for affective and schizophrenic psychoses. European Archives of Psychiatry and Clinical Neuroscience 2008, 258:37-40.
31. Mueller J.C., Lõhmussaar E., Mägi R., Remm M., Bettecken T., Lichtner P., et al. Linkage disequilibrium patterns and tagSNP transferability among European populations. American Journal of Human Genetics 2005, 76:387-398.
32. Numakawa T., Yagasaki Y., Ishimoto T., Okada T., Suzuki T., Iwata N., et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Human Molecular Genetics 2004, 13:2699-2708.
33. Oeth P., Beaulieu M., Park C., Kosman D., Del Mistro G., Van Den Boom D., et al. iPLEX™ assay: increased plexing efficiency and flexibility for MassARRAY system through single base primer extension with mass-modified terminators http://www.agrf.org.au/docstore/snp/iPlex.pdf.
34. Ohayon M.M., Schatzberg A.F. Prevalence of depressive episodes with psychotic features in the general population. American Journal of Psychiatry 2002, 159:1855-1861.
35. Oyama S., Yamakawa H., Sasagawa N., Hosoi Y., Futai E., Ishiura S. Dysbindin-1, a schizophrenia-related protein, functionally interacts with the DNA-dependent protein kinase complex in an isoform-dependent manner. PLoS One 2009, 4:e4199.
36. Pae C.U., Drago A., Kim J.J., Patkar A.A., Jun T.Y., Lee C., et al. DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. Neuroscience Letters 2008, 440:150-154.
37. Pae C.U., Mandelli L., De Ronchi D., Kim J.J., Jun T.Y., Patkar A.A., et al. Dysbindin gene (DTNBP1) and schizophrenia in Korean population. European Archives of Psychiatry and Clinical Neuroscience 2009, 259:137-142.
38. Pae C.U., Serretti A., Mandelli L., De Ronchi D., Patkar A.A., Jun T.Y., et al. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenetics and Genomics 2007, 17:69-75.
39. Pae C.U., Serretti A., Mandelli L., Yu H.S., Patkar A.A., Lee C.U., et al. Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. American Journal of Medical Genetics B Neuropsychiatric Genetics 2007, 144B:701-703.
40. Park N., Juo S.H., Cheng R., Liu J., Loth J.E., Lilliston B., et al. Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Molecular Psychiatry 2004, 9:1091-1099.
41. Peters K., Wiltshire S., Henders A.K., Dragović M., Badcock J.C., Chandler D., et al. Comprehensive analysis of tagging sequence variants in DTNBP1 shows no association with schizophrenia or with its composite neurocognitive endophenotypes. American Journal of Medical Genetics B - Neuropsychiatric Genetics 2008, 147B:1159-1166.
42. Raybould R., Green E.K., MacGregor S., Gordon-Smith K., Heron J., Hyde S., et al. Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biological Psychiatry 2005, 57:696-701.
43. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7:426-437.
44. Schatzberg A.F. New approaches to managing psychotic depression. Journal of Clinical Psychiatry 2003, 64:19-23.
45. Schatzberg A.F., Rothschild A.J. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?. American Journal of Psychiatry 1992, 149:733-745.
46. Schulze T.G., Ohlraun S., Czerski P.M., Schumacher J., Kassem L., Deschner M., et al. Genotype-phenotype studies in bipolar disorder showing association between the DAOA/G30 locus and persecutory delusions: a first step toward a molecular genetic classification of psychiatric phenotypes. American Journal of Psychiatry 2005, 162:2101-2108.
47. Schwab S.G., Knapp M., Mondabon S., Hallmayer J., Borrmann-Hassenbach M., Albus M., et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. American Journal of Human Genetics 2003, 72:185-190.
48. Serretti A., Benedetti F., Mandelli L., Calati R., Caneva B., Lorenzi C., et al. Association between GSK-3beta -50T/C polymorphism and personality and psychotic symptoms in mood disorders. Psychiatry Research 2008, 158:132-140.
49. Serretti A., Lattuada E., Catalano M., Smeraldi E. Serotonin transporter gene not associated with psychotic symptomatology of mood disorders. Psychiatry Research 1999, 86:59-65.
50. Steffens M., Lamina C., Illig T., Bettecken T., Vogler R., Entz P., et al. SNP-based analysis of genetic substructure in the German population. Human Heredity 2006, 62:20-29.
51. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. American Journal of Human Genetics 2002, 71:337-348.
52. Talbot K., Eidem W.L., Tinsley C.L., Benson M.A., Thompson E.W., Smith R.J., et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. Journal of Clinical Investigation 2004, 113:1353-1363.
53. Thakur M., Hays J., Krishnan K.R. Clinical, demographic and social characteristics of psychotic depression. Psychiatry Research 1999, 86:99-106.
54. Van Den Bogaert A., Schumacher J., Schulze T.G., Otte A.C., Ohlraun S., Kovalenko S., Becker T., Freudenberg J., Jönsson E.G., Mattila-Evenden M., Sedvall G.C., Czerski P.M., Kapelski P., Hauser J., Maier W., Rietschel M., Propping P., Nöthen M.M., Cichon S. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. American Journal of Human Genetics 2003, 73:1438-1443.
55. Van Den Bogaert A., Del-Favero J., Van Broeckhoven C. Major affective disorders and schizophrenia: a common molecular signature?. Human Mutation 2006, 27:833-853.
56. van den Oord E.J., Sullivan P.F., Jiang Y., Walsh D., O'Neill F.A., Kendler K.S., et al. Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Molecular Psychiatry 2003, 8:499-510.
57. Voisey J., Swagell C.D., Hughes I.P., Lawford B.R., Young R. Morris CP. Analysis of HapMap tag-SNPs in dysbindin (DTNBP1) reveals evidence of consistent association with schizophrenia. European Psychiatry 2010, 25:314-319.
58. Wildenauer D.B., Schwab S.G., Maier W., Detera-Wadleigh S.D. Do schizophrenia and affective disorder share susceptibility genes?. Schizophrenia Research 1999, 39:107-111.
59. Williams N.M., Preece A., Morris D.W., Spurlock G., Bray N.J., Stephens M., et al. Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch Gen Psychiatry 2004, 61:336-344.
60. Wirgenes K.V., Djurovic S., Agartz I., Jonsson E.G., Werge T., Melle I., et al. Dysbindin and d-amino-acid-oxidase gene polymorphisms associated with positive and negative symptoms in schizophrenia. Neuropsychobiology 2009, 60:31-36.
61. Wray N.R., James M.R., Handoko H.Y., Dumenil T., Lind P.A., Montgomery G.W., et al. Association study of candidate variants from brain-derived neurotrophic factor and dystrobrevin-binding protein 1 with neuroticism, anxiety, and depression. Psychiatric Genetics 2008, 18:219-225.
62. Yagasaki Y., Numakawa T., Kumamaru E., Hayashi T., Su T.P., Kunugi H. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. The Journal of Biological Chemistry 2006, 281:12941-12949.
63. Yoshimizu T., Shimazaki T., Ito A., Chaki S. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology 2006, 186:587-593.
64. Zill P., Baghai T.C., Engel R., Zwanzger P., Schüle C., Eser D., et al. The dysbindin gene in major depression: an association study. American Journal of Medical Genetics B - Neuropsychiatric Genetics 2004, 129B:55-58.